- Everything we could find out about it

Home ] [ Controlled Substances ] [ Hallucinogens ]

Created Feb 2021




DEA CODE 7390: Schedule 1

There are six possible analogues of TMA:

  • TMA:
    3,4,5 trimethoxyamphetamine
    Dose: 100-250 mg Duration: 6-8 h
    Effects: Similar to mescaline but perhaps less pleasant. More active.
    This is the amphetamine analogue of mescaline, and may be derrived from elemicin, a fraction of nutmeg oil.
  • TMA-2:
    2,4,5 trimethoxyamphetamine
    Dose: 20-40 mg Duration: 8-12 h
    Effects: Strongly psychedelic, somewhat similar to mescaline. Pleasant.
    Derrived from assarone, a component of calamus oil.
  • TMA-3:
    2,3,4 trimethoxyamphetamine
    Not found to be active at 100 mg
  • TMA-4:
    2,3,5 trimethoxyamphetamine
    Slight activity (~= 50 ug LSD) found at 80 mg ca. 6 h
  • TMA-5:
    2,3,6 trimethoxyamphetamine
    Mild stimulant and psychedelic effects found at 30 mg (~75 ug LSD) 8-10 h
  • TMA-6:
    2,4,6 trimethoxyamphetamine
    Dose: 25-50 mg Duration: 12-16 h
    Effect: Very pleasant stimulant and psychedelic

TMA-1 was the first psychotomimetic drug synthesized in 1947 by modifying the structure of mescaline on the basis of the principles discovered in studying the relationships between chemical structures and biological activity, and has about twice the potency of mescaline.

TMA-2, the geometric isomer of TMA-1, was first synthesized in 1933, and its psychotomimetic properties were first reported by Shulgin in 1964. This was thus called TMA-2 as the second of the six possible positional isomers found to be psychotomimetic. TMA-2 was reported to possess some 20 times the potency of mescaline and is the most active of the six isomers of TMA.

The remaining isomers were numbered by Shulgin in the order of their progressive position of substitution, as abbreviated above. The values for relative human potencies of TMA-4, -5, and -6 compared to that of mescaline were evaluated to be 4, 10, and 10, respectively. TMA-3 was found to exhibit no psychotomimetic activity. The isomers, except TMA-3, have both stimulant and psychedelic effects, and their qualitative effects on mood alteration and sensory enhancement are similar to those of mescaline. Although their physical health risks and toxic doses in humans have never been clarified, mental health risks are assumed to be similar to those of other hallucinogens.


Synthesised in 1947, TMA-2 is one of the numerous 'new synthetic drugs' with no legitimate therapeutic use that are described in Shulgin's Pikhal. TMA-2 can be produced from the active agent asarone, which is extracted from the rhizome of the plant Acorus calamus. The precursor asarone is widely used as an active principle in food flavourings. TMA-2 has the structural characteristics of amphetamines, which are associated with hallucinogenic and stimulant actions. It is an analogue that is very close to TMA but is 10 times more potent (20 mg of TMA-2 induces the same hallucinogenic effects as 200 mg of TMA). Therefore it carries potential risks common to TMA and other hallucinogenic substances (e.g. DOM, DOB)


There are occasional references to the use of TMA-2 in early 1970's counter-culture publications, describing the drug as being rarely produced for sale and expensive in comparison to LSD. This suggests that there was only very limited human usage of TMA-2 between its invention and the publication of its synthesis and pharmacology in Shulgin's 1991 book PiHKAL. Since then it has been regarded as an oddball and a novelty in the psychedelics community and is only occasionally sought after intentionally. In terms of its subjective effects, it is known for its lack of classic psychedelic visuals compared to its parent compound (mescaline) and is known instead for its instead a unique stimulating body-high and altered headspace that ranges from euphoric to dysphoric variably.

Anecdotal reports suggest that TMA-2 is a highly unpredictable and dose-sensitive substance that can produce uncomfortable amounts of body load, nausea, overstimulation, and inconsistencies between experiences.

In modern times, TMA-2 is used as an obscure recreational drug and a occasional entheogen. It is rarely sold on the streets and is almost exclusively obtainable as a grey area research chemical through the use of online vendors.

TMA-2 Duration:

Trimethoxyamphetamine-2, a psychedelic amphetamine and stimulant first synthesised by Alexander Shulgin. An uncommon compound of similar activity to other psychedelic amphetamines. Short history of human use.

RouteOnsetDurationAfter Effects
Tripsit Factsheets
All ROAs:20-120 minutes6-12 hoursPossibly hours
TMA-2 Duration
Euphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.

Cayman Chemical PDF TMA

Cayman Chemical PDF TMA-2

  • A family of isomeric psychedelic hallucinogenic drugs.
  • There exist six different TMAs that differ only in the position of the three methoxy groups: TMA, TMA-2, TMA-3, TMA-4, TMA-5, and TMA-6.
  • The TMAs are analogs of the phenethylamine cactus alkaloid mescaline.
  • First synthesized in 1947.

The most important TMA compound from a pharmacological standpoint is TMA-2, as this isomer has been much more widely used as a recreational drug and sold on the grey market as a so-called "research chemical"; TMA (sometimes referred to as "mescalamphetamine" or TMA-1) and TMA-6 have also been used in this way to a lesser extent. These three isomers are significantly more active as hallucinogenic drugs, and have consequently been placed onto the illegal drug schedules in some countries such as the Netherlands and Japan. The other three isomers TMA-3, TMA-4 and TMA-5 are not known to have been used as recreational drugs to any great extent, and remain obscure scientific curiosities.

The TMAs are substituted amphetamines, however, their action does not resemble that of the unsubstituted compound amphetamine, which is a stimulant and not a psychedelic. It is reported that some TMA's elicit a range of emotions ranging from sadness to empathy and euphoria.

Related Substances:
Created Feb 2021



DEA CODE 7390: Schedule 1

A positional isomer of TMA (3,4,5-trimethoxyamphetamine)


First synthesised in the 50s, this uncommon drug was reexamined by David Nichols in the 1990s. It is an analogue of mescaline which is roughly six times more potent, and is thus a powerful psychedelic phenethylamine. Subjective effects may include stimulation and hallucinations.

RouteOnsetDurationAfter Effects
Tripsit Factsheets
All ROAs:1.5-2 hours8-12 hours3-5 hours
Escaline Duration
Euphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.
It is a closely related structural analog of mescaline with which it shares many common properties. Escaline was first synthesized and reported in the scientific literature by Benington, et al. , in 1954, but was later re-examined in the laboratory of David E. Nichols who prepared a series of mescaline analogues, including proscaline, jimscaline, isoproscaline, and others. The effects of escaline were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story. He lists the dosage range as 40 mg to 60 mg orally and describes the duration of action to be 8 - 12 hours. Shulgin states that escaline "differs from mescaline in that the onset of action is quicker (within the first hour) and there is no nausea noted, but otherwise the time course, and much of the qualitative content, is quite similar. "

In comparison to mescaline, this compound has significantly more negative physical side effects, less insightful cognitive effects and less complex visual effects.

Tolerance and addiction potential
Escaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating. Tolerance to the effects of escaline is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). Escaline presents cross-tolerance with all psychedelics, meaning that after the consumption of escaline all psychedelics will have a reduced effect.

Escaline Interactions


  • With 40 mg:
    This is a powerful and complex intoxicant - I could not have coordinated any rational muscular activity. I could not walk; I could not tie my shoe-laces. There is analgesia and an incoordination that I cannot shake. My menstrual flow started a bit ahead of time, but it was light.
  • With 50 mg:
    I felt that the body tensions outweighed the psychological and sensory rewards, in that I had a lot of dehydration and my sleep had a nightmare quality. This pretty much offset the few virtues that I felt I had obtained.
  • With 60 mg:
    There is a quality of rational analysis and insight that is totally impressive. Many subtle factors in my life can be viewed with insight, and usefully dissected. I got into a deep discussion, but I was not argumentative or even defensive and I remained detached and kept a tone of cool impersonality. I had a good appetite. But I also had some tachycardia and muscular tension. There was unquestionable sensory enhancement, but without an intellectual component. Overall it was most pleasant.

In an isolated situation, there is easy fantasy, but little synthesis of external sensory inputs such as music or visual stimulae. A gradual decline brings the subject back to a restful baseline somewhere before the 12th hour. The following day is often seen as one of tiredness and low energy. An anonymous flyer appeared in the California drug community in 1984 stating an effective range to be 50 to 100 milligrams, but it described the drug as the sulfate. The above data all pertain to the hydrochloride salt.

Cayman Chemical PDF Escaline

SWGDRUG PDF Escaline Monograph

  • A positional isomer of TMA (3,4,5-trimethoxyamphetamine)
  • A psychedelic drug
  • First synthesized and reported in the scientific literature in 1954
  • Mescaline analog
  • The duration of action stated to be 8 - 12 hours
  • 3,5-methoxy-4-ethoxyphenethylamine
  • 2-(4-Ethoxy-3,5-dimethoxy-phenyl)-ethylamine
  • 3,5-Dimethoxy-4-ethoxy-phenethylamine
  • 2-(4-Ethoxy-3,5-dimethoxyphenyl)ethanamine

The effects of this and related mescaline analogues in humans were first described by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin lists the dosage range as 40 to 60 mg, consumed orally

Syndromes of Thrombotic Microangiopathy - Rapidly available testing for drug-dependent antibodies is needed to ... End-stage renal disease and the recurrence of TMA appear to be prevented by replacement treatment. The benefits of plasma ...
Saturday September 02, 2023 -

Omeros Corp: Continues To Offer Great Trading Opportunities - Omeros Corp. (OMER), which faces regulatory hurdles but a diverse pipeline of drug candidates, may offer trading opportunities for risk-tolerant investors. Read more here.
Wednesday February 14, 2024 -

TMA workers protest ‘firing’ by QWP workers - He denied his men opened fire on TMA workers. JAILED: Additional district and sessions judge/model court Abdul Hasan Mohmand awarded life imprisonment and a fine of Rs0.5 million to a drug dealer ...
Wednesday February 14, 2024 -

Thermal Analysis System TMA/SDTA 2+ from Mettler Toledo - The Thermal Analysis System TMA/SDTA 2+ from Mettler Toledo can be utilized for an extensive range of applications, thanks to its wide temperature range and the extensive choice of force ...
Tuesday May 19, 2020 -

Your Guide To Using At-Home Covid Tests - Note that these tests differ from home collection tests, which the Food and Drug Administration (FDA ... in a lab using gold standard RT-PCR/TMA. LetsGetChecked aims to deliver online results ...
Thursday February 01, 2024 -

DNAnexus and TMA Precision Health Join Forces to Improve Diagnostics and Treatment Options for Rare Diseases - BOSTON, January 23, 2024--(BUSINESS WIRE)--DNAnexus, Inc., the provider of the Precision Health Data Cloud, and TMA Precision Health, a global health platform for rare diseases, today announced a ...
Monday January 22, 2024 -

Suspects in major drug bust begin court process - Feb. 9—The nine individuals arrested during a multi-location Mon Metro Drug Task Force drug bust last week were scheduled for preliminary hearings in Monongalia County Magistrate Court on Wednesday, ...
Friday February 09, 2024 -

Two new ECCs go live with TMA’s Automated Secure Alarm Protocol - TMA’s ASAP service is designed to increase the accuracy and efficiency of calls for service from alarm monitoring centers to Emergency Communication Centers (ECCs). Related To: The Monitoring ...
Wednesday January 24, 2024 -

TMA Chicago Midwest Podcast Hosted by Paul Musser | Jack O'Connor Talks 'Success Through Service' [PODCAST] - We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...
Sunday February 18, 2024 -

Thermomechanical Analyzers (TMA) - Thermomechanical Analysis or TMA is a form of thermal analysis. It measures the change in dimension of a material with changing temperature while a load is applied. The technique is most often ...
Friday August 14, 2020 -

Total Energies Marketing Maroc TMA - Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Tuesday January 16, 2024 -

Northampton A4500 Weedon Road closed after flooding - A main road into Northampton has been closed due to flooding, with motorists urged to find alternative routes. The A4500 Weedon Road is inaccessible eastbound, from junction 16 of the M1, west of ...
Saturday February 17, 2024 -

Hallucinogens | Link to this page

Home ] [ Controlled Substances ] [ Sources ]

· Controlled Substances
· Hallucinogens
· Tma